Followers | 128 |
Posts | 2150 |
Boards Moderated | 1 |
Alias Born | 12/27/2007 |
Wednesday, April 09, 2014 8:20:33 AM
Sodium Thiosulfate (STS) Phase 3 Clinical Study Update ..READ
Looks like we hit the Jackpot here ...Maybe this is the reason for the heavy buying by Insiders ! This Low float sleeping giant will explode if final results is also positive .GL
-------
Adherex Announces Sodium Thiosulfate Clinical Study Update
~ Data have been submitted to ASCO 2014~
Adherex’s collaborator the Children’s Oncology Group (COG) posted top-line results from a Phase III trial of Adherex’s lead candidate STS to clinicaltrials.gov last week. The data are incomplete and no statistical analysis was performed. A full analysis of secondary endpoints such as event free survival and overall survival was not posted. Any interpretation should be limited until Adherex reports the full data, which is expected at the American Society of Clinical Oncology (ASCO) meeting in June 2014.
Posted Data, though Incomplete, is Encouraging. According to the posted results, the data regarding the frequency of patients with hearing loss is encouraging, and may support the primary endpoint after a full statistical analysis. The primary endpoint of the trial is hearing protection in pediatric oncology patients undergoing platinum-based chemotherapy.
The posted data show that out of 56 patients in the cisplatin arm of the study, 31 (55%) experienced hearing loss. For the 49 patients treated with STS and cisplatin, 14 (29%) experienced hearing loss. Information posted on the website is incomplete and final results may differ from those presented.
Adherex has announced that COG has already submitted an abstract for presentation at 2014 American Society of Clinical Oncology Meeting. The Company indicated that no other study data is available for public disclosure at this time.
Recent FENC News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/05/2024 09:02:25 PM
- Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 09/05/2024 10:56:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 10:48:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 10:33:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/04/2024 08:05:38 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 08/27/2024 09:30:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2024 09:51:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 11:02:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 11:01:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 11:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 10:59:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 09:10:11 PM
- Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/13/2024 10:05:00 AM
- Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024 • GlobeNewswire Inc. • 08/06/2024 08:31:00 PM
- Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director • GlobeNewswire Inc. • 08/05/2024 10:26:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:30:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/01/2024 08:21:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:08:11 PM
- Fennec Pharmaceuticals Announces Management Change • GlobeNewswire Inc. • 07/01/2024 10:00:00 AM
- Fennec Announces Results of Annual Meeting • GlobeNewswire Inc. • 06/25/2024 08:35:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 10:21:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 09:12:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 08:29:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:05:25 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM